|
1
|
Pollard C, Smith SC and Theodorescu D:
Molecular genesis of non-muscle-invasive urothelial carcinoma
(NMIUC). Expert Rev Mol Med. 12:e102010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Murta-Nascimento C, Schmitz-Dräger BJ,
Zeegers MP, Steineck G, Kogevinas M, Real FX and Malats N:
Epidemiology of urinary bladder cancer: from tumor development to
patient’s death. World J Urol. 25:285–295. 2007.
|
|
3
|
Hassen W and Droller MJ: Current concepts
in assessment and treatment of bladder cancer. Curr Opin Urol.
10:291–299. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hirata H, Hinoda Y, Ueno K, Shahryari V,
Tabatabai ZL and Dahiya R: MicroRNA-1826 targets VEGFC,
beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer.
Carcinogenesis. 33:41–48. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Paik JH, Kollipara R, Chu G, Ji H, Xiao Y,
Ding Z, Miao L, Tothova Z, Horner JW, Carrasco DR, Jiang S,
Gilliland DG, Chin L, Wong WH, Castrillon DH and DePinho RA: FoxOs
are lineage-restricted redundant tumor suppressors and regulate
endothelial cell homeostasis. Cell. 128:309–323. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Myatt SS, Wang J, Monteiro LJ, Christian
M, Ho KK, Fusi L, Dina RE, Brosens JJ, Ghaem-Maghami S and Lam EW:
Definition of microRNAs that repress expression of the tumor
suppressor gene FOXO1 in endometrial cancer. Cancer Res.
70:367–377. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guttilla IK and White BA: Coordinate
regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast
cancer cells. J Biol Chem. 284:23204–23216. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim TH, Jo SW, Lee YS, Kim YJ, Lee SC, Kim
WJ and Yun SJ: Forkhead box O-class 1 and forkhead box G1 as
prognostic markers for bladder cancer. J Korean Med Sci.
24:468–473. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bansal N, Yendluri V and Wenham RM: The
molecular biology of endometrial cancers and the implications for
pathogenesis, classification, and targeted therapies. Cancer
Control. 16:8–13. 2009.PubMed/NCBI
|
|
10
|
Goto T, Takano M, Albergaria A, Briese J,
Pomeranz KM, Cloke B, Fusi L, Feroze-Zaidi F, Maywald N, Sajin M,
et al: Mechanism and functional consequences of loss of FOXO1
expression in endometrioid endometrial cancer cells. Oncogene.
27:9–19. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fei X, Qi M, Wu B, Song Y, Wang Y and Li
T: MicroRNA-195-5p suppresses glucose uptake and proliferation of
human bladder cancer T24 cells by regulating GLUT3 expression. FEBS
Lett. 586:392–397. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Várallyay E, Burgyán J and Havelda Z:
MicroRNA detection by northern blotting using locked nucleic acid
probes. Nat Protoc. 3:190–196. 2008.PubMed/NCBI
|
|
13
|
Guo Y, Liu J, Xu Z, Sun K and Fu W: HLA-B
gene participates in the NF-kappaB signal pathway partly by
regulating S100A8 in the laryngeal carcinoma cell line Hep2. Oncol
Rep. 19:1453–1459. 2008.PubMed/NCBI
|
|
14
|
Engels BM and Hutvagner G: Principles and
effects of microRNA-mediated post-transcriptional gene regulation.
Oncogene. 25:6163–6169. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stenvang J, Silahtaroglu AN, Lindow M,
Elmen J and Kauppinen S: The utility of LNA in microRNA-based
cancer diagnostics and therapeutics. Semin Cancer Biol. 18:89–102.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
Downing JR, Jacks T, Horvitz HR and Golub TR: MicroRNA expression
profiles classify human cancers. Nature. 435:834–838. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Han Y, Chen J, Zhao X, Liang C, Wang Y,
Sun L, Jiang Z, Zhang Z, Yang R, Chen J, et al: MicroRNA expression
signatures of bladder cancer revealed by deep sequencing. PLoS One.
6:e182862011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ozsolak F, Poling LL, Wang Z, Liu H, Liu
XS, Roeder RG, Zhang X, Song JS and Fisher DE: Chromatin structure
analyses identify miRNA promoters. Genes Dev. 22:3172–3183. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang H, Regan KM, Wang F, Wang D, Smith
DI, van Deursen JM and Tindall DJ: Skp2 inhibits FOXO1 in tumor
suppression through ubiquitin-mediated degradation. Proc Natl Acad
Sci USA. 102:1649–1654. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hoekstra AV, Ward EC, Hardt JL, Lurain JR,
Singh DK, Buttin BM, Schink JC and Kim JJ: Chemosensitization of
endometrial cancer cells through AKT inhibition involves FOXO1.
Gynecol Oncol. 108:609–618. 2008. View Article : Google Scholar : PubMed/NCBI
|
